FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
about
Treatment of Gram-positive infections in critically ill patientsCeftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycinCeftaroline fosamil: a brief clinical review.Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE.Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trialsChanging needs of community-acquired pneumonia.Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia.Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unitCeftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolatesAssessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible Staphylococcus aureus: Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo ExposuresTreatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury.Neutropenia Associated with Long-Term Ceftaroline UseProspective study of the Wilson severity-of-illness scoring system for complicated skin and skin structure infections.Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort.Revolutionising bacteriology to improve treatment outcomes and antibiotic stewardship.Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.Daptomycin Failure for Treatment of Pulmonary Septic Emboli in Native Tricuspid and Mitral Valve Methicillin-Resistant Staphylococcus aureus Endocarditis.Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.Ceftaroline fosamil: a new broad-spectrum cephalosporin.Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline FosamilComparative in vitro activities of ceftaroline and ceftriaxone against bacterial pathogens associated with respiratory tract infections: results from the AWARE surveillance study.In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.Rate and Incidence of Adverse Reactions Associated With Ceftaroline Exposure: Importance of Cutaneous Manifestations.
P2860
Q27015976-3B2596C4-3F42-4E7D-B876-FE52B816229FQ31033921-69593182-9E8B-45A8-9BC4-EA2E59643BF7Q33657212-6E251F2A-BD1E-42C7-AD44-E5DDBDEE38DFQ33798268-7337A25D-06F9-418E-BB9B-CCB96663A4F1Q33939080-9DDD05F8-9B7D-45CE-9029-581E39897053Q34726283-129B607F-7E77-47E1-B2B4-089C4F0655A2Q35105955-A0EEC8A6-28F7-4E4F-A1FB-57533EBC3D9EQ35127530-DF93359D-2485-4ACE-BE4B-265AFDE92FBBQ35408518-6A0AF3DF-B0B1-41FA-893D-3909A2D7BCC2Q35427862-33203D80-09B2-4E95-9EAF-81ECC94427DAQ35545954-422F3DE5-C78A-437C-9580-A0A515903DDCQ35941308-FBB7019F-16AD-4664-8F56-88FC120900CFQ36096382-EF1AC8D8-0713-4FC6-9DB4-8FE802C630A8Q36363239-B950BCB8-F31E-401A-B6DC-8623BE476BC1Q36439140-AF2BBC1C-655B-4D74-89AA-89C4C09C2C5AQ36505476-058E6A20-5593-47F0-8C97-28013A7B9FB5Q37080538-2CFEFF20-50FA-4B03-AAC9-172ECCFBEFEFQ37192145-160AFFC5-56F7-46B2-AD15-DECF5C9E941AQ37287884-589FA5DE-B2FB-48D0-9DA3-4F251817C329Q37335859-A419E2F7-487C-4AE2-8C4F-E76731954CBFQ37382998-AEF7E481-C6BC-4894-90AC-597E5FAC3A3FQ37713010-B78B2FEC-8894-4ED2-B4A5-B233BE825BD9Q37863942-05855A94-4908-4E63-8D35-B38363F81BC5Q38006689-9D9BB918-AFC5-4527-873F-CDC7DBA854E4Q38025132-CA1FACCA-79DD-4B36-AC26-177A5F4A9DBAQ38061168-F8E8953E-8CE9-499E-A602-B39F5C9633E4Q38117077-D795A00C-1DC5-4956-ACAB-C0368462A492Q38987098-10882D6A-764F-4C5E-9B16-AEF59719A621Q39226965-904E35B5-5317-4103-85B4-F8C4D1D4F50FQ39455499-03738086-BD03-407D-B4FC-2745BD57014DQ41713696-798A2CF6-F0DB-48D0-922B-D0DAE00A045EQ41907687-392D8442-CBFF-48D9-8902-5D694EF1DD58Q41984202-8F812DC6-D501-4378-9533-F551F76F76FAQ41985451-FCBF916A-B53B-42DE-8BD7-3F2DF70E6DBFQ45340895-F97264B6-B7CA-42BD-9B3C-52EAB4E442F8Q47660954-95F31CEE-85E8-4329-A8D0-51A72FA80829
P2860
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
FOCUS 1: a randomized, double- ...... community-acquired pneumonia.
@en
FOCUS 1: a randomized, double- ...... community-acquired pneumonia.
@nl
type
label
FOCUS 1: a randomized, double- ...... community-acquired pneumonia.
@en
FOCUS 1: a randomized, double- ...... community-acquired pneumonia.
@nl
prefLabel
FOCUS 1: a randomized, double- ...... community-acquired pneumonia.
@en
FOCUS 1: a randomized, double- ...... community-acquired pneumonia.
@nl
P2093
P2860
P921
P356
P1476
FOCUS 1: a randomized, double- ...... community-acquired pneumonia.
@en
P2093
Dirk A Thye
Donald E Low
FOCUS 1 investigators
George H Talbot
H David Friedland
Ian A Critchley
Lily Llorens
Paul B Eckburg
Thomas M File
P2860
P304
P356
10.1093/JAC/DKR096
P407
P478
66 Suppl 3
P577
2011-04-01T00:00:00Z